Restricted accessLetterFirst published online 2026
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab
GiovannoniGSoelberg SørensenPCookS, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the CLARITY study. N Engl J Med2010; 362(5): 416–426.
HavrdovaEBelovaAGoloborodkoA, et al. Activity of secukinumab, an anti–IL-17A antibody, on MRI lesions in relapsing–remitting multiple sclerosis: A randomized, placebo-controlled study. J Neurol2016; 263(7): 1287–1295.
4.
MadillEGalettaKOpeyemiO, et al. Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: A multi-center exploratory study. J Clin Neurosci2025; 136: 111211.
5.
ChaitidisNSakellariouGTDavitiM, et al. Safety and efficacy of IL-17 inhibitors in patients with comorbid multiple sclerosis/multiple sclerosis-like syndrome: A systematic review. Rheumatol Int2025; 45(6): 147.
